Nuoyi Mai'er Secures Nearly RMB 300 Million Series C Funding to Advance Regenerative Medical Materials

Recently, Jinbo Biomedical Technology Co., Ltd. (hereinafter referred to as "Jinbo") has announced more good news. The company's important innovative achievement, recombinant type III humanized collagen protein, has successfully obtained a Brazilian patent authorization. This good news not only marks that Jinbo's recombinant humanized collagen protein technology innovation capabilities continue to gain international recognition but also injects new momentum into the company's expansion in the global market.(Source:Jinbo

On January 10, Sciwind announced that it had reached a global development and commercialization licensing and cooperation agreement with Verdiva Bio for a portfolio of three products, including the once-weekly oral GLP-1 receptor agonist Enotuglutide, covering all regions outside Greater China and South Korea. The total amount could reach up to 2.47 billion US dollars.

Verdiva, Focused on Developing Innovative Therapies for Obesity and Other Cardiovascular Metabolic Disorders, Announced Its Establishment Yesterday and Completed a $411 Million Series A Financing Round, Co-led by Forbion and General Atlantic, with Other Investors Including RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.(Source of information:Insight Database

Recently, Neo Modulus (Suzhou) Medical Sci-Tech Co., Ltd. announced the completion of a nearly 300 million yuan C-round financing. This round of financing was led by Shenzhen Capital Group's New Materials Fund for Manufacturing Transformation and Upgrading, with participation from some existing shareholders and management. WinX Capital served as the exclusive financial advisor for this round of financing.

Neo Modulus stated that the funds from this round of financing will mainly be used for the commercial promotion, clinical trials, and implementation of international strategies for the company's multiple innovative medical device products.

Data shows that Neo Modulus, founded in March 2017, is an innovative enterprise engaged in the research, production, and commercialization of regenerative implantable medical devices.(Source of information:(Caijing.com)

HAIRO Hair Transplant Robot, independently developed by Pangce Medical, has officially obtained the medical device registration certificate issued by the National Medical Products Administration (NMPA).

Question from Investors:

The review progress of the company's semaglutide has been suspended. What is the reason? Does the company have any relevant information? Secretary Dong answers (Livzon Pharmaceutical Group Inc. (35.540, -0.17, -0.48%) SZ000513):

Dear investors, hello! The development and application of the company's semaglutide injection are proceeding smoothly: the Type II diabetes indication has been submitted for production; the weight loss indication Phase III clinical trial has completed enrollment. Please be informed, thank you!(Source of information:Ask the Secretary of the Board )

On January 15, Suzhou Mecreate announced the completion of an over RMB100 million Series A+ round of financing. This round was jointly led by Sequoia China and EF Capital, with participation from Industrial Securities Capital and QingSong Capital. WinX Capital served as the exclusive financial advisor. The proceeds will be used for the construction of medical implant-grade ePTFE production lines, innovative product research and development, and the commercial promotion of certified products. It is reported that Suzhou Mecreate is a platform company specializing in the R&D, manufacturing, and commercialization of high-end implantable and interventional medical devices based on core technology in medical implant-grade ePTFE materials.(Source of information:Economic Observer Network)

Lilly Chairman and CEO Dave Ricks recently stated that the company expects its experimental oral weight-loss drug to be approved as early as the beginning of 2026, which is approximately one year from now.

David Ricks, CEO of Eli Lilly and Company, said in an interview on the sidelines of the conference that the company expects to obtain experimental data for "orforglipron" by mid-2025, and the drug may be approved early the following year.

He added that, compared to weight-loss injections, pills will be more convenient for patients and easier to mass-produce. The current shortage of weight-loss injections is partly due to production limitations.(Source of information:Cailian Press)

On Tuesday, January 14, Eastern Time, the U.S. pharmaceutical giant Eli Lilly released its full-year 2024 earnings forecast and 2025 earnings guidance.

The company expects revenue of approximately $13.5 billion in Q4 2024, a year-over-year increase of 45%, and full-year revenue of about $45 billion, up 32% year-over-year. However, these figures are below the expected $14 billion and $45.5 billion, respectively.

The company explained that the demand for weight-loss drugs grew less than expected, affecting its performance.(Source:(Gelonghui)

Hengrui Medicine's GLP-1/GIP Dual Receptor Agonist HRS9531, Co-developed with U.S. Company, Achieves Significant 22.8% Weight Loss in Phase II Obesity Clinical Trial, Demonstrating Strong Efficacy, Safety, and Tolerability.(Source of information:Hengrui Medicine

CCTV Exposes the Grey Industrial Chain of Bone-Breaking Height Increase: Bone-lengthening Surgery, Commonly Known as Limb Lengthening Surgery, is a Traumatic Disease Treatment Technology. Since 2006, China’s Health Department Has Prohibited Its Use for Cosmetic Purposes, but in Fact, This Surgery Is Still Being Used for Beauty Enhancement, with Many People Online Claiming They Can Perform It.

Reporters found that some doctors manipulate X-rays and medical records, performing leg-lengthening surgeries under the guise of corrective procedures. "We'll adjust your leg a bit, make it look slightly crooked." "If you don't go through the orthopedic process, who would dare to operate on you? Once the National Health Commission investigates, it's over."

"There is a saying in the 'leg circle': it's like gambling. Xiao Fang, a 'leg friend,' said that many 'leg friends' around him have developed complications. Even without complications, postoperative leg function can hardly be restored to its original level. The decline in athletic ability has brought new troubles to life. 'I feel very uncomfortable every night when I sleep, and I deeply regret having this surgery...'"(Source of information:CCTV News)

Medical aesthetics industry insiders revealed that around January 14, some medical aesthetics institutions had already received notifications from relevant regulatory authorities, requiring them to self-inspect whether they use hydroxyapatite products and whether the used products are legal. If in use, they need to report promptly to ensure no safety issues arise. According to information circulating within the industry, a certain region in Hubei Province issued an internal notice, requesting all medical institutions to carefully review relevant materials, tally whether hydroxyapatite products are used, and submit statistical forms by the day after the notice was issued.(Source of information:21st Century Business Herald )

On January 13, the Linwei District Market Supervision Administration conducted a special rectification campaign targeting the medical aesthetics industry, aiming to further standardize the order of the medical aesthetics sector and effectively protect the legitimate rights and interests of consumers.

During the inspection, law enforcement officers reviewed on-site the business licenses, medical institution practice permits, and other relevant certifications of the medical aesthetics institutions to ensure their legal and compliant operation, eliminating unlicensed or over-scope business activities. They also conducted strict inspections on the procurement channels, storage conditions, and product qualifications of popular medical aesthetics products such as botulinum toxin and hyaluronic acid. At the same time, they investigated and dealt with illegal advertising behaviors according to law, such as false advertising, exaggerated efficacy claims, and the use of absolute terms, guiding medical aesthetics institutions to standardize the content of their advertisements.

During the inspection, law enforcement officers educated the operators of medical aesthetics institutions on relevant laws and regulations, urging them to strictly implement the main responsibility for enterprise safety, standardize business practices, and operate with integrity and in accordance with the law. At the same time, consumers are encouraged to enhance their self-protection awareness, choose正规的医疗美容机构 to receive services, and promptly call the 12315 complaint and reporting hotline if any illegal activities are discovered.

It is reported that since the special rectification campaign was launched, the Linwei District Market Supervision Administration has dispatched more than 160 law enforcement personnel, identified 7 issues, ordered 5 businesses to make corrections, issued 1 warning, and discovered 1 suspected illegal activity, which is currently under investigation.(Source:Huashan Network)

Recently, it was reported that Ms. Wen, on the recommendation of a local friend, paid 9,000 yuan to receive "beauty bone surgery" for nasal alar filling at Zhongxin Technology Beauty. By the end of 2023, due to unsatisfactory results, she contacted the "doctor" who performed the procedure, Mr. Guo Mou Shan, requesting the removal of the implants. Mr. Guo recommended her to undergo surgery at Nanchang Han Shou Medical Aesthetics and promised to cover the costs.

On January 24, 2024, Ms. Wen underwent an implant removal surgery at Nanchang Hanshou Medical Cosmetology. However, her face remained swollen post-operation. The institution explained that it was caused by residual implant material not being fully removed. On November 21, Ms. Wen returned to the facility for facial injection treatment, which resulted in an abscess forming on her right cheek. After diagnosis at the First Hospital of Shanxi Medical University, the possibility of inflammatory abscess formation was confirmed. Following a report to the Comprehensive Health Supervision and Law Enforcement Bureau of Donghu District, Nanchang City, enforcement officers conducted an inquiry with Dr. Yue Mouhui from Nanchang Hanshou Medical Cosmetology. Dr. Yue Mouhui stated that the drugs injected into Ms. Wen's face on November 21 were lipolysis injections and triamcinolone acetonide injections. However, the nurse claimed only triamcinolone acetonide injections were administered. The outpatient medical record noted: "Lipolysis injection + triamcinolone acetonide injection treatment for cheeks," signed by Dr. Yue Mouhui.

The Health Enforcement Bureau of Donghu District, Nanchang City, stated that the preliminary investigation showed that Nanchang Hanshou Medical Cosmetology and its operating doctor had the corresponding qualifications but there were medical quality issues. Regarding whether Ms. Wen's symptoms were related to this institution, professional medical evaluation is required. Additionally, concerning the legality of Taiyuan Zhongxin Technology Beauty Institution and the qualifications of its operators, relevant clues will be transferred to the local health department via official communication. Currently, the Health Enforcement Bureau of Donghu District has legally initiated an investigation into "Nanchang Hanshou Medical Cosmetology." The next step will involve further collecting evidence materials provided by both parties involved to assess and impose corresponding penalties on the institution.